Mark Lewis has become senior vice president of development for Illumina, a new position. He will be responsible for overseeing Illumina's global product development. Lewis joins Illumina from Becton Dickinson Biosciences, where he was most recently vice president of special order research products. Prior to that, he was president of Aeomecia, where he led research initiatives and commercial release of genomic technologies. Before that, he held various positions at Molecular Dynamics, including that of vice president of sequencing technology. Lewis holds a BA in biology from the University of California, San Diego.
William Shanahan has joined the board of directors of Life Technologies. He is the former president of Colgate-Palmolive and currently serves on the board of directors of Visa and MSD Ignition. Shanahan joined Colgate-Palmolive in 1965 and retired from the company in 2005. He received his undergraduate degree from Dartmouth College.
VisiGen Biotechnologies Co-founder, President, and CEO Susan Hardin will continue as the company’s research director, following its acquisition by Invitrogen, which is now part of Life Technologies, according to the University of Houston. Hardin is a former professor of biology and biochemistry at the university.
Five other VisiGen co-founders and UH professors will no longer be associated with the company. They are James Briggs, associate professor of biology and biochemistry, chemical engineering and chemistry; Xiaolian Gao, professor of biology and biochemistry and professor of chemistry; Michael Rea, professor of biology and biochemistry; Shiao-Chun (David) Tu, professor of biology and biochemistry and professor of chemistry; and Richard Willson, professor of chemical and biomolecular engineering and biology and biochemistry.
Anne Wojcicki, co-founder of 23andMe, has joined the board of directors of the Foundation for the National Institutes of Health. She is one of five new board members.